MA40580A - Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques - Google Patents

Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Info

Publication number
MA40580A
MA40580A MA040580A MA40580A MA40580A MA 40580 A MA40580 A MA 40580A MA 040580 A MA040580 A MA 040580A MA 40580 A MA40580 A MA 40580A MA 40580 A MA40580 A MA 40580A
Authority
MA
Morocco
Prior art keywords
integrin
antagonists
beta
alpha
treatment
Prior art date
Application number
MA040580A
Other languages
English (en)
Other versions
MA40580B1 (fr
Inventor
Niall Andrew Anderson
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40580A publication Critical patent/MA40580A/fr
Publication of MA40580B1 publication Critical patent/MA40580B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de formule (i), ce dernier étant un acide 4-(3-fluoro-3-(2-(5, 6, 7, 8-tétrahydro-l, 8-naphthyridin-2-yl) éthyl) pyrrolidin-l-yl)-3-(3-(2-méthoxyéthoxy) phényl) butanoïque, ou un sel de ce dernier.
MA40580A 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques MA40580B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
PCT/EP2015/071776 WO2016046225A1 (fr) 2014-09-26 2015-09-22 Nouveaux composés
EP15767475.5A EP3197892B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Publications (2)

Publication Number Publication Date
MA40580A true MA40580A (fr) 2017-08-02
MA40580B1 MA40580B1 (fr) 2018-09-28

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40580A MA40580B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Country Status (37)

Country Link
US (3) US9956209B2 (fr)
EP (2) EP3197892B1 (fr)
JP (1) JP6611799B2 (fr)
KR (1) KR101998000B1 (fr)
CN (1) CN107074848B (fr)
AR (1) AR101994A1 (fr)
AU (1) AU2015320858B2 (fr)
BR (1) BR112017006251A2 (fr)
CA (1) CA2962315A1 (fr)
CL (1) CL2017000705A1 (fr)
CO (1) CO2017002714A2 (fr)
CR (1) CR20170112A (fr)
CY (1) CY1121071T1 (fr)
DK (1) DK3197892T3 (fr)
DO (1) DOP2017000081A (fr)
EA (1) EA031481B1 (fr)
ES (1) ES2690748T3 (fr)
GB (1) GB201417002D0 (fr)
HR (1) HRP20181796T1 (fr)
HU (1) HUE041827T2 (fr)
IL (1) IL250592A0 (fr)
JO (1) JO3413B1 (fr)
LT (1) LT3197892T (fr)
MA (1) MA40580B1 (fr)
MX (1) MX2017003948A (fr)
PE (1) PE20170502A1 (fr)
PH (1) PH12017500361B1 (fr)
PL (1) PL3197892T3 (fr)
PT (1) PT3197892T (fr)
RS (1) RS58000B1 (fr)
SG (1) SG11201701183YA (fr)
SI (1) SI3197892T1 (fr)
SM (1) SMT201800513T1 (fr)
TW (1) TW201629056A (fr)
UA (1) UA119181C2 (fr)
UY (1) UY36314A (fr)
WO (1) WO2016046225A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
WO2018089353A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
CA3042710A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Composes mono et spirocycliques contenant du cyclobutane et de l'azetidine en tant qu'inhibiteurs de l'integrine .alpha.v
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
PL3538528T3 (pl) * 2016-11-08 2021-05-31 Bristol-Myers Squibb Company Amidy pirolu jako inhibitory integryny alfa v
EP3558303A4 (fr) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. Composés acides aminés et leurs procédés d'utilisation
EP3760202A1 (fr) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
WO2018167295A1 (fr) * 2017-03-17 2018-09-20 Technische Universität München LIGANDS POUR L'INTÉGRINE αVβ8, SYNTHÈSE ET UTILISATIONS DE CEUX-CI
BR112020008893A2 (pt) 2017-11-07 2020-10-13 Bristol-Myers Squibb Company derivados de pirrolopirazina como inibidores de alfa v integrina
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
UY38353A (es) * 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
UY38352A (es) * 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
WO2020047208A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
EP3843728B1 (fr) * 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
MX2021006544A (es) * 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813769A (pt) 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
EP1047425A4 (fr) 1997-12-17 2009-04-22 Merck & Co Inc Antagonistes du recepteur de l'integrine
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
WO2001024797A1 (fr) * 1999-10-04 2001-04-12 Merck & Co., Inc. Antagonistes des recepteurs d'integrine
CN1414966A (zh) 1999-11-08 2003-04-30 麦克公司 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
US7056909B2 (en) 2000-07-26 2006-06-06 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
EP1349548A4 (fr) 2001-01-03 2004-06-02 Merck & Co Inc Methodes et compositions de traitement d'une parodontopathie
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
MXPA04008870A (es) 2002-03-13 2005-06-17 Biogen Idec Inc Anticuerpos anti-avb6.
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2211615A4 (fr) 2007-10-22 2010-10-13 Glaxosmithkline Llc Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (fr) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Dérivés fluorés de l'acide 3-(2-oxo-3-(3-(5,6,7,8-tétrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoïque et leurs utilisations
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
SMT201800513T1 (it) 2018-11-09
US20180271845A1 (en) 2018-09-27
KR101998000B1 (ko) 2019-07-08
MX2017003948A (es) 2017-06-26
PH12017500361A1 (en) 2017-07-17
PT3197892T (pt) 2018-12-12
DK3197892T3 (en) 2018-11-26
EP3428167A1 (fr) 2019-01-16
HRP20181796T1 (hr) 2018-12-28
EA201790715A1 (ru) 2017-07-31
AU2015320858A1 (en) 2017-03-09
MA40580B1 (fr) 2018-09-28
TW201629056A (zh) 2016-08-16
CL2017000705A1 (es) 2017-11-03
US10342783B2 (en) 2019-07-09
SG11201701183YA (en) 2017-04-27
DOP2017000081A (es) 2017-04-30
CY1121071T1 (el) 2019-12-11
CN107074848A (zh) 2017-08-18
US20170290817A1 (en) 2017-10-12
ES2690748T3 (es) 2018-11-22
AU2015320858B2 (en) 2018-10-18
CA2962315A1 (fr) 2016-03-31
AR101994A1 (es) 2017-01-25
CR20170112A (es) 2017-05-26
EP3197892B1 (fr) 2018-09-05
CO2017002714A2 (es) 2017-06-30
US9956209B2 (en) 2018-05-01
US20190275016A1 (en) 2019-09-12
KR20170055489A (ko) 2017-05-19
JP6611799B2 (ja) 2019-11-27
BR112017006251A2 (pt) 2017-12-12
EA031481B1 (ru) 2019-01-31
PH12017500361B1 (en) 2017-07-17
EP3197892A1 (fr) 2017-08-02
RS58000B1 (sr) 2019-01-31
PL3197892T3 (pl) 2019-05-31
WO2016046225A1 (fr) 2016-03-31
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
JO3413B1 (ar) 2019-10-20
HUE041827T2 (hu) 2019-05-28
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
PE20170502A1 (es) 2017-04-27
JP2017528507A (ja) 2017-09-28
UA119181C2 (uk) 2019-05-10
CN107074848B (zh) 2019-11-01
UY36314A (es) 2016-04-29

Similar Documents

Publication Publication Date Title
MA40580A (fr) Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MA35725B1 (fr) Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
PH12016501440A1 (en) Novel heterocyclic compounds
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MX378717B (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
MA40302A1 (fr) Dérivés de carbazole
WO2015100092A3 (fr) Analogues 7-bêta d'orvinols
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EP3854220A4 (fr) Additif alimentaire pour bétail comprenant du n-acétyl-l-tryptophane en tant que principe actif
EP4036095A4 (fr) Composés de pyrazolopyridine utiles en tant qu'inhibiteurs sélectifs de la btk kinase
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
EA033085B1 (ru) Производные 2-(1-гетероарилпиперазин-4-ил)метил-1,4- бензодиоксана в качестве альфа2c-антагонистов
EA201600507A2 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
MA42602B1 (fr) Antagonistes du recepteur cgrp